ClinicalTrials.gg
Not yet recruitingNCT06742970TELEFRAIL TAVIUpdated Dec 19, 2024

Telematic Intervention for Reversing Frailty Among Older Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Intervention. the TELE-FRAIL TAVI Clinical Trial

An interventional study of Telematic intervention in Aortic Stenosis, sponsored by Spanish Society of Cardiology. Not yet recruiting at 1 site in Spain. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Spanish Society of Cardiology · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Aortic Valve Stenosis with a site in Spain — 25 open to participants now, 32 under way, 1 of them phase 3. Aortic Valve Stenosis · Spain.

Planned enrollment
20th of 37
206 · median 209
Started
2025
with 4 others
No phase
26 of 83
12 open now
Primary completion
2025-09
later than 10 of 31 live
Registered
73rd of 83
by date

Among the 83 studies in Aortic Valve Stenosis with a site in Spain, this one is the 20th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2025, is one of 26 with no phase, reaches primary completion later than 10 of the 31 other live ones, and was the 73rd registered.

Aortic Valve Stenosis

1,027 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

25 of the 83 studies in Aortic Valve Stenosis with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Aortic Valve Stenosis with a site in Spain, or all of them as a file.
02

Study summary

The TELE FRAIL clinical trial is a randomized trial designed to compare, among older frail patients with aortic stenosis undergoing transcatheter valve intervention (TAVI), the impact of usual care after vs a telematic intervention (including a supervised exercise training program, nutrition and education) on frailty reversal and clinical outcomes three months after the TAVI procedure.

The trial will include older patients a with baseline frailty criteria with severe AS undergoing TAVI. A comprehensive geriatric assessment will be performed after the TAVI procedure in all patients.

Inclusion criteria will be: a) patients aged 75 years or older; b) severe symptomatic aortic stenosis, as defined by a mean aortic gradient≥40 mmHg and/or an aortic valve area \< 1cm2 measured by transtoracic echocardiography; c) performance of successful TAVI during the admission, and d) baseline frailty criteria, as defined by Short Physical Performance Battery test value \<10 and a FRAIL scale value ≥3.

Exclusion criteria will be: a) negative to participate in the trial; b) unability to undergo a comprehensive geriatric assessment or study related procedures ; c) unability to complete clinical follow up, and d) life expectancy lower than one year.

Patients will be randomized (1:1) to intervention or control arms before hospital discharge after the TAVI procedure.

Patients assigned to the intervention will undergo a telematic intervention during the first 90 days after the admission. Trained nurses form an specialized company will contact patients by videocalls at weeks 1,3,5,7,9,11 an12 months. This telematic intervention will include 1) a supervised exercise program (based on an adaptation of the VIVI-FRAIL program) during this 12 weeks; 2) nutrition intervention: The investigator team will provide patients with nutrition supplements for the first 12 weeks after the admission. Patients will take daily a dose of 200 ml of hypercaloric hyperproteic supplements one hour after performing the corresponding exercise training session. Patients will also receive information about the optimal dieta adapted to their clinical profile; and c) health education about the disease, the importance of adherence to medical treatments and recommendations and the best measures for preventing complications.

Main outcome measured will be the proportion of patients with frailty (as measured by a Short Physical Performance Battery test value \<10) 3 months after the admission.

Secondary outcomes will include 1) the number of days alive out of hospital during the first year, 2) need for readmission at 3 months and at one year, 3) overall mortality at one year, 4) incidence of cardiovascular events (myocardial infarction, need for unplanned revascularization or stroke) at 3 months and at one year, 5) proportion of frail patients (SPPB\<10) at one year, 6)disability for acitivies of daily living (Barthel index) at three months and at one year, 7) nutritional risk (as measured by the MA-Sf test) at three months and at one year and 8) quality of life (as defined by the EQ-5D-5L test) at three months and at one year.

Read the detailed description

**Introduction** Degenerative aortic stenosis (AS) is the most common valvular disease in Western countries, largely due to increased life expectancy and the progressive aging of the population. Percutaneous aortic valve replacement (TAVI) has revolutionized the treatment of AS, demonstrating its effectiveness in inoperable patients, high-risk patients, and recently even in patients with low or intermediate surgical risk. This increasing evidence has led to a steady rise in TAVI procedures annually, generating a need for healthcare systems to adapt and optimize healthcare pathways and hospital stays.

AS is a disease predominantly associated with aging. The presence of frailty, comorbidities, and other geriatric syndromes is strongly linked to complications, the need for readmissions, and mortality both in conservatively treated patients and those undergoing surgery or TAVI. Frailty and comorbidity burden are also associated with a higher incidence of procedure-related complications, despite technological advances making TAVI increasingly less invasive. Previous data suggest that patients with greater comorbidity burden have higher rates of readmission and extracardiac mortality, which can limit the benefit of TAVI and even negate it in some highly comorbid patients. Therefore, optimizing patient selection to avoid the futility of the procedure remains a key clinical challenge.

Frailty is a phenotype characterized by vulnerability to potential external stressors, and it may be reversible. In patients with cardiovascular diseases, a significant part of frailty is due to heart disease itself, and therefore potentially reversible with its specific treatment. However, in patients with a higher comorbidity burden, it can be challenging to determine what proportion of frailty is due to other health conditions. It has been suggested that managing frail patients requires a comprehensive approach for frailty reversal, including physical exercise, proper nutrition, and strict control of comorbidities that may accelerate frailty progression. Some publications have shown that physical exercise programs can partially reverse frailty in various cardiovascular settings, including AS patients. However, implementing these strategies in clinical practice presents significant challenges, including the cost of enrolling a growing number of patients in cardiac rehabilitation programs and the difficulty in achieving sustained adherence to these programs.

Telemedicine presents potential advantages, especially in managing elderly patients with frailty and cardiovascular diseases, by enabling proper follow-up while avoiding logistical barriers such as transportation and suboptimal adherence, particularly relevant in this context. Different telemedicine-related tools have proven useful in improving outcomes for patients with heart failure by detecting early decompensation and preventing hospital admissions and other complications. However, there is no experience with applying telemedicine to frail patients with AS undergoing TAVI.

The primary objective of the TELE-FRAIL TAVI clinical trial is to analyze the effect of a comprehensive telehealth intervention on frailty reversal at 3 months post-TAVI compared to standard management in patients with AS undergoing TAVI.

**Methods**

**Study Design** This is a prospective, multicenter, randomized (1:1) study designed to compare a comprehensive telehealth intervention for frailty versus usual post-discharge management in patients aged ≥75 years with AS and frailty criteria undergoing TAVI. The study will be conducted across 20 hospitals in Spain, involving clinical and interventional cardiologists, geriatricians, and other experts in managing these patients, as well as trained nursing staff.

**Study Population**

  • Inclusion Criteria:** Patients eligible for inclusion are those who meet the following criteria: 1) Severe AS, defined as a mean aortic gradient >40 mmHg or aortic valve area \<0.8 cm² on echocardiography; 2) Age ≥75 years; 3) Underwent TAVI during hospitalization; 4) Baseline frailty criteria (pre-procedure) defined as a score of \<10 on the Short Physical Performance Battery (SPPB) and a score of ≥3 on the FRAIL scale.
  • Exclusion Criteria:** 1) Refusal to participate in the study; 2) Inability to perform geriatric assessments or comply with study procedures; 3) Inability to understand or sign informed consent; 4) Life expectancy \<12 months.

In addition to the defined criteria, the inclusion of the patient in the study and the derived procedures must be deemed reasonable by the medical team responsible for the patient. Any complications that arise during hospitalization must be reasonably resolved as a prerequisite for inclusion in the study.

**Treatment Protocol**

Before undergoing the TAVI procedure, a baseline geriatric evaluation will be conducted through an interview with the patient and/or family or caregivers. This evaluation will be multidisciplinary, involving trained staff from the participating centers and will include:

  • Functional capacity for basic daily activities, assessed by the Barthel Index.
  • Instrumental activities, assessed by the Lawton-Brody Index.
  • Cognitive status assessed by the Pfeiffer Test, as well as the Mini Mental State Examination.
  • Frailty assessment using the SPPB.
  • Comorbidity assessment using the Charlson Index, with a maximum score of 37 points.

Patients with frailty criteria who agree to participate in the study will be randomized before hospital discharge (after TAVI) into two possible treatment arms: a) Comprehensive telehealth intervention (nutrition + supervised physical exercise + health education) for the first 90 days; or b) Usual post-discharge management. Randomization will be computer-generated in a 1:1 ratio.

**Frailty Intervention** The intervention will be carried out telematically in the first 90 days post-discharge by a specialized company. Healthcare professionals specialized in nutritional support and physical exercise adapted to frail patients will conduct weekly video calls after discharge, followed by calls at 15 days and every 2 weeks for the first 3 months. The physical exercise program will use an adaptation of the VIVI FRAIL program.

  • Nutritional Support:** Patients assigned to the frailty intervention arm will receive appropriate nutritional information tailored to their profile after hospital discharge. Nutritional supplements will be provided for the first 3 months post-discharge, consisting of a hypercaloric and hyperproteic formula taken once daily after completing the exercise regimen.
  • Health Education:** During video calls over the first 3 months, patients will receive additional information on nutrition and exercise, and any questions will be answered. Patients will also be provided with information to optimize adherence to therapeutic regimens and control cardiovascular risk factors.

**Outcome Measures**

The primary outcome measure is the percentage of patients with frailty reversal, measured by SPPB (i.e., achieving an SPPB score ≥10) at 3 months post-discharge. Secondary outcomes include:

  • Number of days alive and out of hospital during the first year post-TAVI.
  • Readmission rate (cardiac and non-cardiac causes) at 3 months and 1 year post-TAVI.
  • Overall and cardiovascular mortality at 3 months and 1 year post-TAVI.
  • Incidence of cardiovascular events (myocardial infarction, stroke, or revascularization) at 1 year post-TAVI.
  • Percentage of patients remaining robust (SPPB >10) at 1 year post-TAVI.
  • Disability (defined by Barthel Index at 3 months and 1 year post-TAVI).
  • Nutritional risk (defined by MNA-SF at 3 months and 1 year post-TAVI).
  • Quality of life (defined by EQ-5D-5L at 3 months and 1 year post-TAVI).

**Geriatric Evaluation During Follow-Up** This will be conducted in-person by trained personnel at participating centers, blinded to the treatment arm. The following aspects will be reevaluated at 3 months and 1 year: functional capacity (Barthel Index), instrumental activities (Lawton-Brody Index), nutritional risk (MNA-SF), cognitive capacity (Pfeiffer Test), quality of life (EQ-5D-5L), and frailty using FRAIL, Clinical Frailty Scale, SPPB, and Essential Frailty Toolset scales. Clinical follow-up includes an in-person clinical visit at 3 months and 1 year.

**Study Committees** This project is an independent clinical trial with no funding from the industry, promoted by the investigative team. A steering committee will be responsible for supervising the scientific and operational aspects of the study. Patients and investigators will not be blinded to treatment arm allocation, but clinical events will be evaluated by an event adjudication committee blinded to treatment allocation to avoid bias. Similarly, a data safety monitoring board will be responsible for making pertinent recommendations to the steering committee regarding the outcome measures and any possible safety observations.

**Statistical Analysis and Sample Size** Previous data from elderly patients with AS and frailty criteria treated with TAVI show an approximate 50% frailty reversal rate after the TAVI procedure. Assuming an estimated 70% frailty reversal in the telehealth intervention arm, with an 80% statistical power, a bilateral alpha error of 0.05, and assuming a 10% loss to follow-up, a sample size of 206 patients (103 patients per arm) is calculated. To achieve the proposed sample size, a multicenter approach is necessary.

All statistical comparisons will be made under the intention-to-treat principle. Results will be presented as frequencies and percentages or median (standard deviation), as appropriate. Group comparisons will be conducted using Fisher's exact test. Patient follow-up will be censored at the time of death or the end of the study. Primary outcome measures will be compared between the two groups using a logistic regression model, considering frailty reversal as the dependent variable, the intervention as the fixed independent variable, and other covariates with significant association included in the final statistical model. In addition to the secondary outcome measures, the effect of the intervention on clinical events will be described using a Kaplan-Meier method, with a Cox regression model employed for evaluation. Hazard ratios (HR) and their 95% confidence intervals (CI) will be calculated. For all analyses, a p-value \<0.05 will be considered statistically significant. Pre-specified subgroup analyses will be performed based on gender and comorbidity burden (Charlson Index).

**Ethical Aspects** Participants and their families will receive detailed information about the risks and potential benefits of study participation. Informed consent documents will be evaluated by the relevant ethics committee. Participants will be given the opportunity to carefully read the consent document and ask questions before signing it. All participants must sign the informed consent document before inclusion in the study. A copy of the consent document will be provided to participants. The rights and welfare of participants will be protected, emphasizing that the quality of medical care will not be negatively affected if they refuse to participate in the study.

**Discussion** Despite TAVI being established as the treatment of choice for the majority of elderly patients with AS, avoiding futility in patients with high comorbidity burden, frailty, and disability remains a clinical challenge. A significant percentage of elderly patients with AS exhibit frailty, partly due to their heart condition (which can be potentially reversed with specific treatment) and partly due to other comorbidities. It has been described that in patients with greater comorbidity burden, treating their AS in isolation may not provide clinical benefit in the absence of other measures. Understanding each patient's profile in detail is crucial for correctly managing AS and their overall condition once valvulopathy has been corrected.

Frailty is considered an intermediate state in the transition to disability that is potentially reversible, especially in its early stages. For this reason, a holistic multidisciplinary approach is important, supported by pillars such as physical exercise, adequate nutrition, and strict control of comorbidities. Some exercise programs have been shown to partially reverse frailty in various cardiovascular settings, including AS patients. However, implementing these strategies in clinical practice presents significant logistical challenges, as well as difficulties in achieving sustained adherence to these programs.

The TELE FRAIL TAVI clinical trial aims to analyze the potential impact of a comprehensive intervention on frailty reversal and prognosis in frail elderly patients undergoing TAVI. It is hoped that the telematic nature of the intervention will enable high adherence to recommendations on physical exercise and nutrition, contributing to frailty reversal alongside correction of AS through TAVI. The study design should allow for a description of the percentage of patients in whom frailty reverses through this combined strategy compared to the TAVI and conventional follow-up strategy, as well as a description of the clinical and geriatric profile of patients in whom this strategy fails and for whom TAVI is likely to be futile. Therefore, the results of the TELE FRAIL TAVI clinical trial are expected to provide valuable insights into the management of frail elderly patients with AS undergoing TAVI, with significant clinical, economic, and social implications for optimizing their management and prognosis.

03

Conditions studied

  • Aortic Stenosis

Keywords

  • frailty
  • aortic stenosis
  • TAVI
  • exercise
  • nutrition
  • older
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • older patients with aortic stenosis undergoing TAVI
  • baseline frailty criteria (SPPB \<10)

Exclusion criteria

Exclusion Criteria:

  • unability to sign
  • unability to complete geriatric assessment
  • unability to complete follow up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
206 participants (estimated)

Study arms

  • No intervention
    Usual care after TAVI

    3 months usual care after TAVI

  • Experimental
    Telematic intervention

    Telematic intervention will be performed by a specialized company hired by the investigational team. Trained nurses will contact patients assigned to the intervention groups by videocalls at weeks 1,3,5,7,9,11 and 12 after the admission. The specialized nurses will supervise the exercise program sessions (based on an adaptation of he VIVI FRAIL program), correcting potential mistakes and recommending the optimal way for performing the training program. Patients will take a 200 ml dose of hyperproteic, hypercaloric nutrition supplements daily one hour after performing the exercise session. Information about the optimal diet adapted to the clinical profile of patients will be also provided. Additionally, health information about the disease, the importance of adherence to treatments and recommendations and the best measures for controling cardiovascular risk factors, comorbidities and avoiding clinical complications will be also provided

    Combination Product: Telematic intervention

Interventions

  • Combination productTelematic intervention

    Telematic intervention will be performed by a specialized company hired by the investigational team. Trained nurses will contact patients assigned to the intervention groups by videocalls at weeks 1,3,5,7,9,11 and 12 after the admission. The specialized nurses will supervise the exercise program sessions (based on an adaptation of he VIVI FRAIL program), correcting potential mistakes and recommending the optimal way for performing the training program. Patients will take a 200 ml dose of hyperproteic, hypercaloric nutrition supplements daily one hour after performing the exercise session. Information about the optimal diet adapted to the clinical profile of patients will be also provided. Additionally, health information about the disease, the importance of adherence to treatments and recommendations and the best measures for controling cardiovascular risk factors, comorbidities and avoiding clinical complications will be also provided

06

What researchers measure

Primary outcomes

  1. frailty 3 months after the admission

    SPPB value \<10

    Time frame: 3 months after the admission

07

Study locations

1 site
  • Calle de Nuestra Señora de Guadalupe, Nº 5 y 7 28028, Madrid (España)
    Madrid, 28028, Spain
08

References and documents

Individual participant data

Plan to share: Undecided — to be defined

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Sep 2025, 8 months later.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 8 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2024
First posted
Dec 19, 2024
StartEst.
Jan 2025
Primary completionEst.
Sep 2025
CompletionEst.
Dec 2025
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742970
Lead sponsor
Spanish Society of Cardiology
Collaborators
Societat Catalana de Cardiologia
Responsible party
Blanca Miranda Serrano (Dr, Spanish Society of Cardiology) — Principal investigator
First posted
Dec 19, 2024
Start date
Jan 2025 (estimated)
Primary completion
Sep 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Dec 19, 2024

Study contacts

Blanca Miranda Serrano BMS Dr, MD
Contact
0034-91724 23 70

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion